The Economic Impact of Clinical Pharmacist Involvement in the Public Procurement for Medicines and in the Drug and Therapeutics Committee

NCT ID: NCT04314336

Last Updated: 2020-12-17

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 10000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-08-01
• Study Completion Date: 2020-06-01

Brief Summary

The investigators have performed cost-minimisation analysis and compared the expenses based on the plan for public procurement (without clinical pharmacist involvement) for drugs with the results of public procurement based on the revised plan for public procurement by the clinical pharmacist. The plan for public procurements was based on the 1 year quantity for each medicine used by the hospital in the previous year, based on the latest deliverable prices at the time of extracting the data to workbook for MS Excel program (ver. 2002, Microsoft, Redmond, WA, USA).

The investigators have performed cost-minimisation analysis and compared the expenses for all received requests for medicines to the drug and therapeutics committee (DTC) for a decision in the 1 year period, before and after involvement of clinical pharmacist in the committee work. The expenses were based on approval decisions in the 1 year period for approval time period. The denial decisions were also calculated and reported. The denial period calculated in rationalisation of expenses were based on 1 year treatment period.

Conditions

Rationalization

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Interventions

Public procurement

Cost minimisation study through public procurement

Intervention Type: DRUG

Drug and Therapeutics Committee

Cost minimisation analysis of results of the drug and therapeutics committee before and after clinical pharmacist involvement

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• All patients in the hospital (inhospital patients)

Exclusion Criteria

• None

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bjelovar General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Eugen Javor

MPharm, Clinical Pharmacist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

General Hospital Bjelovar

Bjelovar, , Croatia

Countries

Croatia

Other Identifiers

1520192020

Identifier Type: -

Identifier Source: org_study_id